LOS ANGELES, CA / ACCESSWIRE / February 23, 2021 / The need for wearable sensors that record real-time body signals and are optimized for use in industrial and military environments remains exceptionally strong. The critical requirements of these chemosensors are longevity and ruggedness, qualities that Grapheton’s core technology is well suited for. Eyeing the growing global market for chemical sensors that is projected to be $30 billion by 2023, US Nuclear’s (OTCQB:UCLE) partner Grapheton has developed novel chemosensors which can be integrated into a wearable device. These devices can be used to monitor the health, safety, and performance of individuals in real-time, reducing risk from things such as infectious diseases, heat stroke or cold exposure, psychological stress, exhaustion, unwanted effects from medicines, or other conditions impacting health.
Multiple sensors can be integrated into a single wearable device. Grapheton’s chemosensors are made of a special glassy carbon (GC) material, which has many advantages over traditional thin-film sensors: they don’t corrode and are designed to resist biofouling – lasting 40 years or more, can withstand electrical stimulation of more than 3.5 billion pulses compared to a mere 10’s of million pulses of thin-film metal electrodes, are ideal for electrophysiology and electrochemical recordings as a biochemical sensor, and can be integrated into flexible substrates to provide a better fit, lessening the inflammatory reactive response. Some common chemicals sensed by glassy carbon include: cortisol (stress level monitoring), glucose, glutamate, and lactate (metabolism monitoring), Ca2+, Na+ – K (dehydration monitoring), dopamine and serotonin (neural chemistry monitoring), ascorbic acid, uric acid, urea, H2O2, pH, and steroid hormones.
The data collected from the GC chemosensors will be processed and analyzed to enable effective real-time decision making while providing an overview of both individual and team performance. The costs of occupational fatalities, illnesses, and injuries exceed $250 billion annually in the US alone and the COVID-19 pandemic has only exacerbated the situation. Grapheton’s rugged GC chemosensors will provide reliable real-time monitoring, helping to improve workplace safety and worker health, as well as finding use in other applications such as monitoring the sick or elderly, high-performance athletes, or military personnel operating under difficult conditions in challenging environments.
Beginning in Q1 2021, Grapheton’s plan is to identify use cases, analyze the existing wearables market, adapt GC chemosensors for human use, and design innovative wearables with integrated chemosensors.
The broader market for Grapheton’s products is in implantable devices, biocompatible chips, wearable devices, on-chip supercapacitors, and on-chip thin-film transistors. Grapheton is currently assembling a Scientific Advisory Board of top industry professionals which will be helpful in identifying opportunities (including grants), building on the company’s strengths, and serving as ambassadors to promote the products.
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com
US Nuclear Corp. (OTCQB:UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
SOURCE: US Nuclear Corp.
View source version on accesswire.com: